GlassScriptPhysician profile
Qun Xu
NPI 1174681274
$839.43
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $778 · 2021: $61.33.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $220.83 | 2019 | |
| Acadia Pharmaceuticals INC | $180.70 | 2019-2021 | |
| Ucb, INC. | $109.65 | 2019 | |
| Amgen INC. | $80.21 | 2019 | |
| Amneal Pharmaceuticals LLC | $69.52 | 2019 | |
| Mdd US Operations, LLC | $58.38 | 2019 | |
| Alexion Pharmaceuticals, INC. | $24.60 | 2019 | |
| Ge Healthcare | $21.03 | 2019 | |
| Scilex Pharmaceuticals INC. | $19.60 | 2019 | |
| Vertical Pharmaceuticals, LLC | $18.89 | 2019 | |
| Adamas Pharmaceuticals, INC. | $18.22 | 2019 | |
| Avanir Pharmaceuticals, INC. | $17.80 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Qun Xu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.